The Latest Cardiac and Vascular News
IRVINE, Calif., Jan. 31, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook Q4 sales grew 1 percent to $1.35 billion; constant currency1 sales grew 7 percent Q4 TAVR sales were flat; constant currency […]
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards’ chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to […]
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Global […]
LONDON, Nov. 27, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data […]
IRVINE, Calif., Nov. 1, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $750 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $1.7 billion of shares in 2022. Under the […]
IRVINE, Calif., Oct. 27, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights and Outlook Q3 sales of $1.32 billion grew 1 percent; constant currency1 sales grew 7 percent Q3 TAVR sales grew 1 percent; […]
BOSTON, Sept. 17, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients […]
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR). “Patients suffering with debilitating […]
IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR). “Delivering the PASCAL Precision system to clinicians in Europe marks […]
IRVINE, Calif., July 28, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights and Outlook Q2 sales of $1.37 billion were flat versus an elevated prior year; underlying1 sales grew 5 percent Q2 TAVR sales […]
